This study reported that although lorlatinib significantly improved health outcomes, it still cannot be regarded as a cost-effective option compared with crizotinib for patients with untreated advanced ALK+ NSCLC from a US payer perspective. Here, ALK is linked to non-small cell lung carcinoma.